Cubist Systematic Strategies, LLC Cel Sci Corp Transaction History

Cubist Systematic Strategies, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$2.58 - $4.99 $225,422 - $435,991	-87,373 Reduced 67.31%	42,433 $191,000
Q1 2022 May 16, 2022	BUY	$3.93 - $7.7 $48,397 - $94,825	12,315 Added 10.48%	129,806 $510,000
Q4 2021 Feb 14, 2022	BUY	$7.1 - $12.82 $834,186 - $1.51 Million	117,491 New	117,491 $834,000
Q3 2021 Nov 15, 2021	SELL	$7.64 - $12.49 $249,751 - $408,298	-32,690 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$8.68 - $27.49 $283,749 - $898,648	32,690 New	32,690 $284,000

7.5M

61.8K

141K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $47.3M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.